PARLIAMENTARY WRITTEN QUESTION
Tirzepatide (21 October 2024)

To ask the Secretary of State for Health and Social Care, with reference to his Department's press release entitled Landmark collaboration with largest pharmaceutical company, published on 14 October 2024, how many times will a patient be allowed to take a course of Mounjaro, in the context of the five year trial in Greater Manchester.

Asked by:
Lee Anderson (Reform UK)

As announced on 14 October 2024, the SURMOUNT-REAL clinical trial of tirzepatide, brand name Mounjaro, is being developed between Health Innovation Manchester, The University of Manchester, and Eli Lilly and Company, with further details about the study to be published at a later date by these organisations, following on from relevant approvals.

Answered by:
Andrew Gwynne (Independent)
30 October 2024